CSPG4
Summary: A human melanoma-associated chondroitin sulfate proteoglycan plays a role in stabilizing cell-substratum interactions during early events of melanoma cell spreading on endothelial basement membranes. CSPG4 represents an integral membrane chondroitin sulfate proteoglycan expressed by human malignant melanoma cells. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| chondroitin sulfate proteoglycan 4 | MIM:601172 | Ensembl:ENSG00000173546 | HGNC:HGNC:2466 | PA26963 | 15q24.2 |
GO terms in CSPG4
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IPI | GO:0019901 | protein kinase binding |
| BP | IEA | GO:0000187 | activation of MAPK activity |
| BP | IEA | GO:0001525 | angiogenesis |
| BP | IEA | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway |
| BP | IEA | GO:0008283 | cell proliferation |
| BP | IEA | GO:0008347 | glial cell migration |
| BP | TAS | GO:0030206 | chondroitin sulfate biosynthetic process |
| BP | TAS | GO:0030207 | chondroitin sulfate catabolic process |
| BP | TAS | GO:0030208 | dermatan sulfate biosynthetic process |
| BP | IDA | GO:0035556 | intracellular signal transduction |
| BP | IEA | GO:0048771 | tissue remodeling |
| BP | IDA | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation |
| CC | TAS | GO:0005576 | extracellular region |
| CC | TAS | GO:0005796 | Golgi lumen |
| CC | TAS | GO:0005887 | integral component of plasma membrane |
| CC | HDA | GO:0005925 | focal adhesion |
| CC | HDA | GO:0009986 | cell surface |
| CC | TAS | GO:0009986 | cell surface |
| CC | IEA | GO:0016324 | apical plasma membrane |
| CC | IEA | GO:0031258 | lamellipodium membrane |
| CC | TAS | GO:0043202 | lysosomal lumen |
| CC | HDA | GO:0062023 | collagen-containing extracellular matrix |
| CC | HDA | GO:0070062 | extracellular exosome |
Gene expression in normal tissue: CSPG4
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in CSPG4
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| pid | integrin1_pathway | Beta1 integrin cell surface interactions |
| wikipathways | WP2431 | Spinal Cord Injury |
| reactome | R-HSA-1430728 | Metabolism |
| reactome | R-HSA-1630316 | Glycosaminoglycan metabolism |
| reactome | R-HSA-1638091 | Heparan sulfate/heparin (HS-GAG) metabolism |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-1793185 | Chondroitin sulfate/dermatan sulfate metabolism |
| reactome | R-HSA-1971475 | A tetrasaccharide linker sequence is required for GAG synthesis |
| reactome | R-HSA-2022870 | Chondroitin sulfate biosynthesis |
| reactome | R-HSA-2022923 | Dermatan sulfate biosynthesis |
| reactome | R-HSA-2024101 | CS/DS degradation |
| reactome | R-HSA-3560782 | Diseases associated with glycosaminoglycan metabolism |
| reactome | R-HSA-3560783 | Defective B4GALT7 causes EDS, progeroid type |
| reactome | R-HSA-3560801 | Defective B3GAT3 causes JDSSDHD |
| reactome | R-HSA-3595172 | Defective CHST3 causes SEDCJD |
| reactome | R-HSA-3595174 | Defective CHST14 causes EDS, musculocontractural type |
| reactome | R-HSA-3595177 | Defective CHSY1 causes TPBS |
| reactome | R-HSA-3781865 | Diseases of glycosylation |
| reactome | R-HSA-4420332 | Defective B3GALT6 causes EDSP2 and SEMDJL1 |
| reactome | R-HSA-71387 | Metabolism of carbohydrates |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD103 | SN-38 | 3 |
| iGMDRD121 | GMX1778 | 2 |
| iGMDRD481 | Dactolisib | 3 |
| iGMDRD77 | Itraconazole | 2 |
| iGMDRD105 | Triptolide | 1 |
| iGMDRD434 | BMS-536924 | 2 |
| iGMDRD329 | Merck60 | 3 |
| iGMDRD871 | BRD6368 | 3 |
| iGMDRD42 | Vorinostat | 3 |
| iGMDRD322 | FK 866 | 2 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD512 | nutlin 3 | 1 |
| iGMDRD84 | Lovastatin acid | 2 |
| iGMDRD701 | NVP-AUY922 | 3 |
| iGMDRD150 | RITA | 6 |
| iGMDRD424 | Tamatinib | 3 |
| iGMDRD154 | NSC23766 | 4 |
| iGMDRD901 | ELCPK | 1 |
| iGMDRD123 | Isoevodiamine | 5 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD138 | PX 12 | 1 |
| iGMDRD506 | Fedratinib | 2 |
| iGMDRD188 | Piperlongumine | 2 |
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD1008 | SR-II-138A | 2 |
| iGMDRD579 | PF750 | 2 |
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD670 | ML 210 | 2 |
| iGMDRD427 | ABT737 | 3 |
| iGMDRD193 | Fqi1 | 2 |
| iGMDRD446 | LY 2183240 | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in CSPG4
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.